Type to search

Artificial Intelligence Fundraising Industry News News

Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence

Share
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence | Pharmtech Focus

Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm (www.Debiopharm.com), announced today their investment in Whitelab Genomics alongside French Venture Capital company, Omnes Capital, in a $10 Million Series A Round to advance their mission to accelerate the development of genomics medicines via technology powered by artificial intelligence (AI). Whitelab Genomics’ computational platform reduces biotherapies’ development time and cost, enabling faster access to the market and cheaper therapeutic solutions available for patients in need. Debiopharm’s investment in Whitelabs Genomics contributes to the growth plan of the start-up’ R&D team and US operations. Such an investment aligns with Debiopharm’s focus on investing in digital health solutions that improve the cancer patient journey, transform pharmaceutical R&D, and shift healthcare towards a more patient-centric approach.

Founded in 2019 by David Del Bourgo, MBA, and Julien Cottineau, Ph.D., alongside a team of world-class data scientists specialized in AI, computational biologists, molecular biologists, and genomic medicine scientists, the start-up offers in-silico simulations customized for target discovery, vector, and payload design, genotoxicity assessment and identification of experimental protocols of in vitro and in vivo strategies.

We’re moving into a time where AI-based technology will play a critical role in drug development. With better ways to develop drugs, de-risk assets, de-risk any toxicity, and ensure efficacy, we’re able to bring more personalized drugs to patients – that’s precisely what Whitelab Genomics is proven to do,” stated Tanja Dowe, CEO of the Debiopharm Innovation Fund.

The value of using this AI-based platform is the potential acceleration of pre-clinical, translational stage, helping drug research companies quickly design payloads and vectors and identify the best experimental protocols for in vitro and in vivo tests,” said Hamzeh Abdul-Hadi, Investment Director of the Debiopharm Innovation Fund.

We are very excited to close this first institutional investment round with such renowned investors with deep knowledge of the pharma environment. With this funding, we can continue developing our proprietary data sets and algorithms for both payload and vectors, and develop our collaborations with our customers,” expressed David Del Bourgo, CEO and co-founder of Whitelab Genomics.

Tags:

People in this post:

Next Up